SecBot SecBot
Biotech Drug Report Generated Jul 7, 2026

solriamfetol

AXSM·Axsome Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (Sunosi, FDA-approved 2019)
Why 4/10
Solriamfetol is already FDA-approved and marketed (Sunosi, since 2019), there is no pending PDUFA or pivotal topline readout in the next ~12 months that would trigger a hard binary stock move. The ADHD FOCUS adult trial succeeded but no sNDA has been filed yet; pediatric ADHD trials (FOCUS-2, FOCUS-3) just began dosing. CLARITY (MDD+EDS) is early. Without a dated binary catalyst, the impact score cannot exceed 5 per the rubric.
Actionable Insight NEUTRAL

Solriamfetol is a steady commercial contributor (~$125M FY2025, 32% YoY) with patent protection through 2040, but it is not Axsome's primary growth driver, Auvelity is larger (~$291M in 2024) and just won an Alzheimer's agitation approval. Watch for whether Axsome files an ADHD sNDA in 2H 2026 or 2027, which would create a new regulatory catalyst. Until then, solriamfetol's value is in its reliable cash flow and pipeline-expansion optionality.

Price Chart

Loading chart...

Executive Summary

Solriamfetol (Sunosi) is an FDA-approved wakefulness drug for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, acquired by Axsome from Jazz Pharmaceuticals in 2022. It generated $124.8M in net product revenue in 2025 (up 32% YoY) and $33.9M in Q1 2026 (up 34%). Patent settlements through June 2026 pushed generic entry to 2040, securing long-term exclusivity. The drug is being expanded into four additional Phase 3 indications: adult/pediatric ADHD (FOCUS adult positive March 2025), MDD with EDS (CLARITY started Feb 2026), binge eating disorder, and shift work disorder. The PARADIGM trial in broad MDD failed in April 2025. Axsome's analyst consensus is Strong Buy (25/27 positive) with a mean target of $276.47 (~45% upside), though solriamfetol is a smaller revenue contributor than Axsome's lead drug Auvelity (~$291M in 2024 plus newly approved for Alzheimer's agitation).

How It Works

Solriamfetol is a wakefulness-promoting medication that works by increasing levels of two brain chemicals, dopamine and norepinephrine (by blocking their reuptake), and also activates a receptor called TAAR1. Think of it as a non-stimulant drug that helps people stay awake and alert, similar in concept to caffeine but stronger and targeted. Unlike traditional stimulants, its mechanism is more selective, which may offer a different side-effect profile.

Trial Status

Solriamfetol (brand name Sunosi) is FDA-approved for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. Three additional Phase 3 trials are in progress or recently completed: (1) FOCUS adult ADHD, positive topline March 2025, sNDA not yet filed; (2) FOCUS-3 (adolescent ADHD), just initiated June 2026; (3) FOCUS-2 (pediatric ADHD), initiated July 2026; (4) CLARITY (MDD with excessive daytime sleepiness), initiated Feb 2026; (5) ENGAGE (binge eating disorder), initiated Apr 2024; (6) SUSTAIN (shift work disorder), initiated Aug 2024. The PARADIGM trial in broad MDD failed its primary endpoint in April 2025 but showed efficacy in the EDS subgroup.

The Two-Sided Case

▲ Bull Case5
Sunosi revenue grew 32% YoY to $124.8M in FY2025 and continued accelerating to 34% growth in Q1 2026 ($33.9M), showing strong commercial execution under Axsome's ownership (source: investingnews.com/Q1 2026 earnings).
Patent settlements with five generic manufacturers block generic competition until 2040 (March or September), securing long-term cash flow from the approved indications (source: fiercepharma.com).
The FOCUS Phase 3 adult ADHD trial met its primary endpoint with a 45% reduction in ADHD symptoms, representing a potential large new indication for a drug with an established safety profile (source: technologynetworks.com).
Solriamfetol is being explored in four additional Phase 3 indications (adolescent/pediatric ADHD, MDD+EDS, BED, shift work disorder), creating multiple shots on goal for label expansion (source: biospace.com).
Axsome has heavy institutional support, Vanguard and BlackRock each hold ~$700M+ positions, and 25 of 27 analysts rate the stock Buy/Strong Buy with a mean price target of $276.47.
▼ Bear Case5
Solriamfetol is a small part of Axsome's overall story, just $124.8M of the company's $638.5M total FY2025 revenue, dwarfed by Auvelity (~$291M in 2024 plus new Alzheimer's agitation approval). Pipeline setbacks may be overlooked if investors focus on the bigger Auvelity/AXS-05 franchise (source: fiercepharma.com).
The PARADIGM Phase 3 trial in broad major depressive disorder failed its primary endpoint in April 2025, revealing limits to solriamfetol's utility as an antidepressant (source: benzinga.com).
No sNDA has been filed for adult ADHD despite positive FOCUS Phase 3 data in March 2025, the regulatory timeline remains unclear, and the company is instead focusing on lengthy pediatric trials that will take years to complete (source: biospace.com).
Adderall, Vyvanse, and other stimulants dominate the ADHD market; solriamfetol (a DNRI) would enter a crowded, established space and face heavy payer/step-therapy hurdles (source: goodrx.com).
CEO Herriot Tabuteau executed a 10b5-1 plan selling ~$11.9M of stock in early July 2026, and CFO Nick Pizzie sold ~$7.9M in June, insider selling of this magnitude near all-time-highs is a potential caution flag.

Upcoming Catalysts

  • Potential sNDA submission for adult ADHD (timeline not yet announced, post-FOCUS positive data from March 2025)
  • Topline CLARITY Phase 3 data for solriamfetol in MDD with excessive daytime sleepiness (enrollment underway, timeline TBD)
  • Topline ENGAGE Phase 3 data for binge eating disorder (enrollment started April 2024)
  • Topline SUSTAIN Phase 3 data for shift work disorder (enrollment started August 2024, estimated completion Dec 2026 per clinicaltrials.gov)
  • FOCUS-3 (adolescent) and FOCUS-2 (pediatric) ADHD Phase 3 enrollment progress

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Axsome Therapeutics, Inc. Press Release AXSM ·Originating report

Sources · 13

Hover a chip for the title
1 investingnews.com2 biospace.com3 technologynetworks.com4 benzinga.com5 fiercepharma.com6 drugs.com7 investingnews.com8 biospace.com9 nasdaq.com10 investingnews.com11 goodrx.com12 en.wikipedia.org13 sec.gov